Literature DB >> 34788420

Efficacy and Outcomes of Faecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection in Children with Inflammatory Bowel Disease.

Maribeth R Nicholson1, Erin Alexander2, Sonia Ballal3, Zev Davidovics4, Michael Docktor3, Michael Dole1, Jonathan M Gisser5, Alka Goyal6, Suchitra K Hourigan7, M Kyle Jensen8, Jess L Kaplan9, Richard Kellermayer10, Judith R Kelsen11, Melissa A Kennedy11, Sahil Khanna2, Elizabeth D Knackstedt8, Jennifer Lentine12, Jeffery D Lewis13, Sonia Michail14, Paul D Mitchell3, Maria Oliva-Hemker15, Tiffany Patton16, Karen Queliza10, Sarah Sidhu15, Aliza B Solomon12, David L Suskind17, Madison Weatherly3, Steven Werlin18, Edwin F de Zoeten19, Stacy A Kahn3.   

Abstract

BACKGROUND: Children with inflammatory bowel disease [IBD] are disproportionally affected by recurrent Clostridioides difficile infection [rCDI]. Although faecal microbiota transplantation [FMT] has been used with good efficacy in adults with IBD, little is known about outcomes associated with FMT in paediatric IBD.
METHODS: We performed a retrospective review of FMT at 20 paediatric centres in the USA from March 2012 to March 2020. Children with and without IBD were compared with determined differences in the efficacy of FMT for rCDI. In addition, children with IBD with and without a successful outcome were compared with determined predictors of success. Safety data and IBD-specific outcomes were obtained.
RESULTS: A total of 396 paediatric patients, including 148 with IBD, were included. Children with IBD were no less likely to have a successful first FMT then the non-IBD affected cohort [76% vs 81%, p = 0.17]. Among children with IBD, patients were more likely to have a successful FMT if they received FMT with fresh stool [p = 0.03], were without diarrhoea prior to FMT [p = 0.03], or had a shorter time from rCDI diagnosis until FMT [p = 0.04]. Children with a failed FMT were more likely to have clinically active IBD post-FMT [p = 0.002] and 19 [13%] patients had an IBD-related hospitalisation in the 3-month follow-up.
CONCLUSIONS: Based on the findings from this large US multicentre cohort, the efficacy of FMT for the treatment of rCDI did not differ in children with IBD. Failed FMT among children with IBD was possibly related to the presence of clinically active IBD.
© The Author(s) 2021. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Crohn’s disease; Ulcerative colitis; child; microbiome

Mesh:

Year:  2022        PMID: 34788420      PMCID: PMC9228903          DOI: 10.1093/ecco-jcc/jjab202

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   10.020


  28 in total

1.  Recurrence rate of clostridium difficile infection in hospitalized pediatric patients with inflammatory bowel disease.

Authors:  Judith R Kelsen; Jason Kim; Dan Latta; Sarah Smathers; Karin L McGowan; Theodore Zaoutis; Petar Mamula; Robert N Baldassano
Journal:  Inflamm Bowel Dis       Date:  2010-08-18       Impact factor: 5.325

2.  Cost-effectiveness analysis of fecal microbiota transplantation for recurrent Clostridium difficile infection.

Authors:  Raghu U Varier; Eman Biltaji; Kenneth J Smith; Mark S Roberts; M Kyle Jensen; Joanne LaFleur; Richard E Nelson
Journal:  Infect Control Hosp Epidemiol       Date:  2015-04       Impact factor: 3.254

3.  Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With Recurrent Clostridium difficile Infection: A Randomized Clinical Trial.

Authors:  Christine H Lee; Theodore Steiner; Elaine O Petrof; Marek Smieja; Diane Roscoe; Anouf Nematallah; J Scott Weese; Stephen Collins; Paul Moayyedi; Mark Crowther; Mark J Ropeleski; Padman Jayaratne; David Higgins; Yingfu Li; Neil V Rau; Peter T Kim
Journal:  JAMA       Date:  2016-01-12       Impact factor: 56.272

4.  Outcomes of Fecal Microbiota Transplantation in Patients With Inflammatory Bowel Diseases and Recurrent Clostridioides difficile Infection.

Authors:  Jessica R Allegretti; Colleen R Kelly; Ari Grinspan; Benjamin H Mullish; Zain Kassam; Monika Fischer
Journal:  Gastroenterology       Date:  2020-07-30       Impact factor: 22.682

Review 5.  The risk of inflammatory bowel disease flares after fecal microbiota transplantation: Systematic review and meta-analysis.

Authors:  Taha Qazi; Thelina Amaratunga; Edward L Barnes; Monika Fischer; Zain Kassam; Jessica R Allegretti
Journal:  Gut Microbes       Date:  2017-09-12

6.  Microbial Engraftment and Efficacy of Fecal Microbiota Transplant for Clostridium Difficile in Patients With and Without Inflammatory Bowel Disease.

Authors:  Robert P Hirten; Ari Grinspan; Shih-Chen Fu; Yuying Luo; Mayte Suarez-Farinas; John Rowland; Eduardo J Contijoch; Ilaria Mogno; Nancy Yang; Tramy Luong; Philippe R Labrias; Inga Peter; Judy H Cho; Bruce E Sands; Jean Frederic Colombel; Jeremiah J Faith; Jose C Clemente
Journal:  Inflamm Bowel Dis       Date:  2019-05-04       Impact factor: 5.325

7.  Fecal transplant for recurrent Clostridium difficile infection in children with and without inflammatory bowel disease.

Authors:  George H Russell; Jess L Kaplan; Ilan Youngster; Mariah Baril-Dore; Lili Schindelar; Elizabeth Hohmann; Harland S Winter
Journal:  J Pediatr Gastroenterol Nutr       Date:  2014-05       Impact factor: 2.839

8.  Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).

Authors:  L Clifford McDonald; Dale N Gerding; Stuart Johnson; Johan S Bakken; Karen C Carroll; Susan E Coffin; Erik R Dubberke; Kevin W Garey; Carolyn V Gould; Ciaran Kelly; Vivian Loo; Julia Shaklee Sammons; Thomas J Sandora; Mark H Wilcox
Journal:  Clin Infect Dis       Date:  2018-03-19       Impact factor: 9.079

9.  Changes in microbial ecology after fecal microbiota transplantation for recurrent C. difficile infection affected by underlying inflammatory bowel disease.

Authors:  Sahil Khanna; Yoshiki Vazquez-Baeza; Antonio González; Sophie Weiss; Bradley Schmidt; David A Muñiz-Pedrogo; John F Rainey; Patricia Kammer; Heidi Nelson; Michael Sadowsky; Alexander Khoruts; Stefan L Farrugia; Rob Knight; Darrell S Pardi; Purna C Kashyap
Journal:  Microbiome       Date:  2017-05-15       Impact factor: 14.650

10.  Long-Term Safety and Efficacy of Fecal Microbiota Transplantation in the Treatment of Clostridium difficile Infection in Patients With and Without Inflammatory Bowel Disease: A Tertiary Care Center's Experience.

Authors:  Obada M Tabbaa; Mohammed M Aboelsoud; Mark C Mattar
Journal:  Gastroenterology Res       Date:  2018-12-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.